文献速递肝病消化道肿瘤与早癌

索拉非尼诱导巨噬细胞焦亡并触发自然杀伤细胞介导的抗肝细胞癌细胞毒性

Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2019-05-21

研究通过两种原位肝细胞癌小鼠模型的体内细胞清除实验及体外分析,发现索拉非尼的抗肿瘤作用依赖巨噬细胞与自然杀伤细胞的相互作用;索拉非尼处理巨噬细胞后诱导焦亡,激活细胞毒性自然杀伤细胞杀伤肿瘤,并下调肿瘤细胞主要组织相容性复合体I类表达;抑制白介素1B和18可削弱索拉非尼疗效。

要点

  • 索拉非尼通过免疫调节发挥作用,巨噬细胞是抗肿瘤效应的关键介导者。
  • 索拉非尼处理巨噬细胞诱导焦亡,并激活细胞毒性自然杀伤细胞杀伤肿瘤。
  • 索拉非尼下调肿瘤细胞主要组织相容性复合体I类表达,可能降低对免疫检查点治疗的响应。

核心结论

  • 索拉非尼的免疫调节机制涉及巨噬细胞焦亡并释放自然杀伤细胞反应,使其有别于其他多靶点激酶抑制剂,有望成为肝细胞癌免疫治疗联合伙伴。

研究设计与样本

  • 研究采用两种原位肝细胞癌小鼠模型的体内细胞清除实验及体外分析。

主要发现

  • 在两种原位肝细胞癌小鼠模型及体外分析中,巨噬细胞是索拉非尼抗肿瘤效应的关键介导者,且巨噬细胞与自然杀伤细胞在有效杀伤肿瘤细胞方面存在强相互依赖性。
  • 索拉非尼处理巨噬细胞后,半胱天冬酶1分析显示焦亡被诱导。
  • 细胞毒性自然杀伤细胞与索拉非尼处理的巨噬细胞共培养时被激活,导致肿瘤细胞死亡。
  • 索拉非尼下调肿瘤细胞主要组织相容性复合体I类表达,可能降低肿瘤对免疫检查点治疗的响应并有利于自然杀伤细胞反应。
  • 体内细胞因子阻断实验显示,抑制白介素1B和18后索拉非尼疗效被削弱。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). We report that sorafenib also acts through direct immune modulation, indispensable for its antitumor activity. In vivo cell depletion experiments in two orthotopic HCC mouse models as well as in vitro analysis identified macrophages (MΦ) as the key mediators of the antitumoral effect and demonstrate a strong interdependency of MΦ and natural killer (NK) cells for efficient tumor cell killing. Caspase 1 analysis in sorafenib-treated MΦ revealed an induction of pyroptosis. As a result, cytotoxic NK cells become activated when cocultured with sorafenib-treated MΦ, leading to tumor cell death. In addition, sorafenib was found to down-regulate major histocompatibility complex class I expression of tumor cells, which may reduce the tumor responsiveness to immune checkpoint therapies and favor NK-cell response. In vivo cytokine blocking revealed that sorafenib efficacy is abrogated after inhibition of interleukins 1B and 18. Conclusion: We report an immunomodulatory mechanism of sorafenib involving MΦ pyroptosis and unleashing of an NK-cell response that sets it apart from other spectrum kinase inhibitors as a promising immunotherapy combination partner for the treatment of HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hage C, Hoves S, Strauss L, et al. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31002440. doi:10.1002/hep.30666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。